# Integration Documentation

## Pharmacovigilance Intelligence System

## 1. Purpose

This document describes how the major components of the Pharmacovigilance Intelligence System work together.

The integration layer connects:

- User/application input
- OpenFDA API retrieval
- Evidence processing
- Evidence normalization
- Schema validation
- Evidence storage
- Automated testing

The objective is to demonstrate how the individual modules form one functional pharmacovigilance evidence pipeline.

---

## 2. Integration Overview

The primary integration flow is:

**User Input → Application → OpenFDA Connector → Retrieved Data → Normalization → Validation → Evidence Store**

Testing provides an additional verification layer across the integrated components.

---

## 3. Main Components

| Component | Location | Integration Role |
|---|---|---|
| Main Application | `app.py` | Coordinates the workflow |
| OpenFDA Connector | `src/openfda_connector.py` | Retrieves external safety data |
| Evidence Schema | `src/evidence_schema.py` | Defines the evidence structure |
| Evidence Normalizer | `src/normalize_evidence.py` | Converts source data into normalized evidence |
| Evidence Store | `src/evidence_store.py` | Stores and manages evidence |
| Automated Tests | `tests/test_phase4.py` | Verifies implemented behavior |

---

## 4. Application to API Integration

The main application communicates with the OpenFDA connector.

The general flow is:

**User enters drug name → Application receives input → Connector creates API request → OpenFDA returns response**

The connector isolates external API communication from the rest of the application.

This means that the application does not need to directly manage all API-specific operations.

---

## 5. OpenFDA Integration

The system integrates with the OpenFDA drug-event API to retrieve publicly available drug safety information.

The integration involves:

1. Receiving a drug name.
2. Constructing the appropriate API request.
3. Sending the request to OpenFDA.
4. Receiving the API response.
5. Processing the returned JSON data.
6. Passing relevant information into the evidence-processing workflow.

The external API is therefore the primary source of the current safety evidence pipeline.

---

## 6. API Response Integration

The OpenFDA API returns structured JSON information.

The application processes the returned information before creating a normalized evidence record.

The conceptual flow is:

**OpenFDA JSON → Parsed Response → Relevant Fields → Normalized Evidence**

Only information required by the internal evidence model should be transferred into the normalized representation.

---

## 7. Normalization Integration

The normalization component connects source-specific data with the internal evidence schema.

The integration flow is:

**Retrieved Source Data → `normalize_evidence.py` → Evidence Schema**

The normalization stage helps convert information from the external source into a consistent internal format.

This reduces dependence on the exact structure of the external API when working with stored evidence.

---

## 8. Schema Integration

The evidence schema defines the expected structure of normalized evidence.

The normalizer produces evidence according to the schema requirements.

The conceptual relationship is:

**Source Data → Normalizer → Evidence Schema → Validated Evidence**

Important evidence fields include:

- `evidence_id`
- `drug_name`
- `drug_identifier`
- `adverse_event`
- `source`
- `source_record_id`
- `evidence_type`
- `event_date`
- `retrieved_at`
- `source_url`
- `schema_version`
- `provenance`
- `raw_record_reference`

---

## 9. Evidence Store Integration

After evidence is normalized and validated, it is passed to the evidence store.

The flow is:

**Normalized Evidence → Evidence Store → Stored Evidence**

The prototype uses structured JSON-based storage.

The evidence store also supports duplicate detection.

---

## 10. Duplicate Integration

Duplicate detection occurs when new evidence is being stored.

The integrated workflow is:

**New Evidence → Compare With Existing Evidence → Duplicate?**

If the evidence is new:

**No → Store Evidence**

If the evidence already exists:

**Yes → Prevent Unnecessary Duplicate Storage**

This protects the evidence store from repeated ingestion of the same record.

---

## 11. Provenance Integration

Provenance information travels with the evidence record through the pipeline.

The flow is:

**External Source → Source Record → Retrieval → Normalization → Validation → Storage**

Important provenance concepts include:

- Source
- Source record reference
- Retrieval timestamp
- Source URL
- Schema version
- Processing information

This allows stored evidence to remain connected to its origin.

---

## 12. Error Handling Integration

Error handling is required at multiple integration boundaries.

### API Boundary

The system should detect unsuccessful API responses and communicate the failure appropriately.

### Data Boundary

The system should handle missing or incomplete source information without inventing values.

### Validation Boundary

Invalid evidence structures should not be treated as valid normalized evidence.

### Storage Boundary

Storage failures should be separated from successful evidence retrieval.

---

## 13. No-Result Integration

The system also handles situations where a search does not return useful safety records.

The workflow is:

**Drug Search → API Request → No Matching Records → No-Result Handling**

A no-result situation should not be interpreted as evidence that the drug is safe.

It only means that the queried source did not return matching records for that request.

---

## 14. Testing Integration

Automated testing verifies that the individual components work together as expected.

The Phase 4 test file is:

`tests/test_phase4.py`

The recorded test command is:

`python -m pytest tests/test_phase4.py -v`

The final recorded result was:

`10 passed`

This provides runtime evidence that the defined automated tests completed successfully.

---

## 15. Integration Test Areas

The completed testing workflow covers important areas of the system, including:

- Evidence schema behavior
- Evidence normalization
- Evidence storage
- Duplicate handling
- API-related behavior
- Error/no-result behavior
- Integration of project components

The exact behavior of each test is defined by the implemented test suite.

---

## 16. End-to-End Integration Flow

The complete conceptual flow is:

**1. User Input**

The user enters a drug name.

↓

**2. Application**

`app.py` receives the input and coordinates the workflow.

↓

**3. OpenFDA Connector**

`src/openfda_connector.py` sends the API request.

↓

**4. External Source**

OpenFDA returns drug-event information.

↓

**5. Processing**

The returned JSON response is parsed and relevant information is extracted.

↓

**6. Normalization**

`src/normalize_evidence.py` converts the information into the normalized evidence representation.

↓

**7. Validation**

`src/evidence_schema.py` verifies the expected evidence structure.

↓

**8. Storage**

`src/evidence_store.py` stores the validated evidence and handles duplicate ingestion.

↓

**9. Retrieval / Review**

Stored evidence can be accessed for further analysis or review.

---

## 17. Integration With Documentation

The implementation is supported by the project's documentation.

### Data Dictionary

`docs/data_dictionary.md`

Defines the evidence fields.

### Dataset Registry

`docs/dataset_registry.md`

Documents the relevant datasets and sources.

### Dataset Evaluation

`docs/dataset_evaluation.md`

Documents dataset evaluation and limitations.

### Learning Notes

`docs/learning_notes.md`

Records technical and research learning.

### Runtime Proof

`docs/runtime_proof.md`

Records runtime verification and testing evidence.

---

## 18. Integration With Evidence Packet

The `evidence_packet/` directory is intended to collect supporting implementation and runtime evidence.

The main areas are:

- `screenshots/`
- `code_packet/`
- `runtime_logs/`
- `api_samples/`
- `deployment_proof/`

These materials can support review of the actual implementation and its execution.

---

## 19. Current Integration Scope

The current integrated system primarily connects the application with OpenFDA/FAERS-related safety evidence.

The following external sources have been considered for broader pharmacovigilance coverage:

- DailyMed
- PubMed / NCBI
- ClinicalTrials.gov
- FDA FAERS

These additional sources are not represented as fully integrated production components unless explicitly implemented in the project.

---

## 20. Current Integration Limitations

The current prototype has the following integration limitations:

- Dependence on OpenFDA API availability
- Dependence on external source data quality
- Limited multi-source integration
- Prototype-level evidence storage
- Limited operational monitoring
- No production-grade deployment architecture
- No automatic clinical causality determination

These limitations should be considered when interpreting system output.

---

## 21. Future Integration

Future versions could integrate additional evidence sources through a common ingestion architecture.

A potential future workflow is:

**OpenFDA + DailyMed + PubMed + ClinicalTrials.gov**

↓

**Source-Specific Connectors**

↓

**Common Evidence Normalization**

↓

**Shared Evidence Schema**

↓

**Validation**

↓

**Unified Evidence Store**

↓

**Search / Signal Detection / Human Review**

This would allow evidence from multiple biomedical sources to be analyzed while preserving the identity and provenance of each source.

---

## 22. Integration Principles

The system follows these integration principles:

### Separation of Responsibilities

Each component has a defined role.

### Source Traceability

Evidence remains connected to its originating source.

### Consistent Representation

Different source information can be normalized into a common evidence structure.

### Error Awareness

External failures and missing information are handled explicitly.

### Duplicate Control

Repeated evidence should not unnecessarily create duplicate stored records.

### Testability

Integrated behavior should be verified through automated tests.

---

## 23. Integration Verification Status

| Integration Area | Status |
|---|---|
| Application → OpenFDA connector | Implemented |
| OpenFDA API retrieval | Implemented |
| Source response processing | Implemented |
| Evidence normalization | Implemented |
| Evidence schema | Implemented |
| Evidence storage | Implemented |
| Duplicate handling | Implemented |
| Error/no-result handling | Implemented |
| Automated integration testing | Completed |
| Recorded automated test result | `10 passed` |

---

## 24. Conclusion

The Pharmacovigilance Intelligence System integrates external drug safety data retrieval with an internal evidence-processing pipeline.

The major integration path is:

**Application → OpenFDA → Processing → Normalization → Validation → Evidence Store**

The system also incorporates provenance preservation, duplicate handling, error handling, and automated testing.

The recorded result of `10 passed` provides evidence that the implemented Phase 4 test suite successfully executed.

The current integration provides a foundation for future expansion into a broader multi-source pharmacovigilance evidence intelligence platform.